KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) EBT Margin (2016 - 2025)

Historic EBT Margin for Sarepta Therapeutics (SRPT) over the last 12 years, with Q2 2025 value amounting to 25.14%.

  • Sarepta Therapeutics' EBT Margin rose 214000.0% to 25.14% in Q2 2025 from the same period last year, while for Jun 2025 it was 20.17%, marking a year-over-year increase of 160400.0%. This contributed to the annual value of 13.71% for FY2024, which is 555400.0% up from last year.
  • Sarepta Therapeutics' EBT Margin amounted to 25.14% in Q2 2025, which was up 214000.0% from 26.08% recorded in Q4 2024.
  • Over the past 5 years, Sarepta Therapeutics' EBT Margin peaked at 26.08% during Q4 2024, and registered a low of 202.25% during Q1 2023.
  • Its 5-year average for EBT Margin is 40.15%, with a median of 25.29% in 2021.
  • As far as peak fluctuations go, Sarepta Therapeutics' EBT Margin crashed by -1528500bps in 2023, and later surged by 2122800bps in 2024.
  • Over the past 5 years, Sarepta Therapeutics' EBT Margin (Quarter) stood at 60.5% in 2021, then skyrocketed by 35bps to 39.2% in 2022, then skyrocketed by 126bps to 10.17% in 2023, then skyrocketed by 156bps to 26.08% in 2024, then dropped by -4bps to 25.14% in 2025.
  • Its EBT Margin stands at 25.14% for Q2 2025, versus 26.08% for Q4 2024 and 7.28% for Q3 2024.